Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | CTSA | P10619 | 14/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3548538 | 0.91 | FFAR1 (0.45) | MEN1KMT2ACTSAFFAR1 | |
| SCHEMBL13564558 | 0.81 | HPGD (0.42) | MEN1KMT2AFFAR1ALDH1A1HPGD | |
| SCHEMBL4798644 | 0.80 | TNK2 (0.38) | MEN1KMT2AHPGD | |
| SCHEMBL3399327 | 0.77 | SLC6A3 (0.38) | MEN1KMT2AFFAR1ALDH1A1HPGD | |
| SCHEMBL4684245 | 0.76 | CTSA (0.50) | CTSAFFAR1 | |
| SCHEMBL13318233 | 0.76 | CTSA (0.50) | CTSAFFAR1 | |
| SCHEMBL3403163 | 0.76 | FFAR1 (0.57) | FFAR1 | |
| SCHEMBL3400389 | 0.76 | SLC6A3 (0.39) | MEN1KMT2AFFAR1ALDH1A1HPGD | |
| SCHEMBL3400381 | 0.76 | SLC6A3 (0.39) | MEN1KMT2AFFAR1ALDH1A1HPGD | |
| SCHEMBL13318386 | 0.76 | FFAR1 (0.57) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| EP-1893582-B1 | Compounds, their pharmaceutical compositions and their use in treating metabolic disorders | AMGEN INC (US) | 2011-12-14 | — | — | EP | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2010-06-03 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-7687526-B2 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2010-03-30 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7582803-B2 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | AMGEN INC. (US) | 2009-09-01 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-7465804-B2 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC. (US) | 2008-12-16 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | AMGEN INC. (US) | 2008-05-22 | — | — | US | disclosed |
| WO-2008030618-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2008-03-13 | — | — | WO | disclosed |
| EP-1893582-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2007033002-A1 | CONFORMATIONALLY CONSTRAINED 3- (4-HYDROXY-PHENYL) - SUBSTITUTED-PROPANOIC ACIDS USEFUL FOR TREATING METABOLIC DISORDERS | AMGEN INC. (US) | 2007-03-22 | — | — | WO | disclosed |
| WO-2006127503-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2006-11-30 | — | — | WO | disclosed |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | AMGEN INC (US) | 2006-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119511-A1 | Benzo-fused compounds for use in treating metabolic disorders | GOT2, PC, GLS2 | MEN1 1317/4885KMT2A 1619/4885CTSA 2834/4885 |
| US-20090275598-A1 | Conformationally constrained 3-(4-hydroxy-phenyl)-substituted-propanoic acids useful for treating metabolic disorders | PC, PNLIP, PDHX | MEN1 991/4885KMT2A 2325/4885CTSA 1166/4885 |
| US-20060270724-A1 | Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders | IAPP, INSR, GPR119 | MEN1 1119/4885KMT2A 3271/4885CTSA 3457/4885 |
| US-20100137323-A1 | BENZO-FUSED COMPOUNDS FOR USE IN TREATING METABOLIC DISORDERS | GOT2, GLS2, PC | MEN1 684/4885KMT2A 1240/4885CTSA 2316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.